Journal of Clinical Epidemiology
Volume 56, Issue 1 , Pages 94-100 , January 2003

Plasma C-reactive protein levels and their relationship to anthropometric and lipid characteristics among children

  • Der-Min Wu

      Affiliations

    • Department of Public Health, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
    • ,
  • Nain-Feng Chu

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Community Medicine, Tri-Service General Hospital, National Defense Medical Center, P.O. Box 90048-509, Nei-Hu, Taipei, Taiwan, ROC, China. Tel: 886-2-8791-0506; fax: 886-2-8791-0590.
    • Department of Public Health, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
    • Department of Community Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
    • ,
  • Muh-Han Shen

      Affiliations

    • Department of Public Health, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
    • ,
  • Jin-Biou Chang

      Affiliations

    • Department of Clinical Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China

Received 3 July 2001 ,Revised 16 May 2002 ,Accepted 30 August 2002.

References 

  1. Steel DM, Whitehead AS. The major acute phase reactants (C-reactive protein, serum amyloid P component and serum amyloid A protein). Immunol Today. 1994;15:81–88
  2. Danesh J, Collins R, Appleby P, et al.  Fibrinogen, C-reactive protein, albumin or white cell count (meta-analyses of prospective studies of coronary heart disease). JAMA. 1998;79:1477–1482
  3. Ridker PM, Rifai N, Pfeffer MA, et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235
  4. Mendall MA, Patel P, Ballam L, et al.  C Reactive protein and its relation to cardiovascular risk factors (a population based cross sectional study). BMJ. 1996;312:1061–1065
  5. Rohde LEP, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol. 1999;84:1018–1022
  6. Tracy RP, Lemaitre RN, Pasty BM, et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly (results from the Cardiovascular Health Study and the Rural Health Promotion Project). Arterioscler Thromb Vasc Biol. 1997;17:1121–1127
  7. Palosuo T, Husman T, Koistinen J, et al.  C-reactive protein in population samples. Acta Med Scand. 1986;220:175–179
  8. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem. 1986;32:142–145
  9. Visser M, Bouter LM, McQuillan GM, et al.  Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–2135
  10. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999;22:1971–1977
  11. Haverkate F, Thompson SG, Pyke SD, et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disability Angina Pectoris Study Group. Lancet. 1997;349:462–466
  12. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  13. Lagrand WK, Visser CA, Hermens WT, et al.  C-reactive protein as a cardiovascular risk factor (more than an epiphenomenon?). Circulation. 1999;100:96–102
  14. Cook DG, Mendall MA, Whincup PH, et al.  C-reactive protein concentration in children (relationship to adiposity and other cardiovascular risk factors). Atherosclerosis. 2000;149:139–150
  15. Ford ES, Galuska DA, Gillespie C, et al.  C-reactive protein and body mass index in children (findings from the Third National Health and Nutrition Examination Survey, 1988–1994). J Pediatr. 2001;138:486–492
  16. Visser M, Bouter LM, McQuillan GM, et al.  Low-grade systemic inflammation in overweight children. Pediatrics. 2001;107:E13
  17. Chu NF, Rimm EB, Wang DJ, et al.  Relationship between anthropometric variable and lipid levels among school children (the Taipei Children Heart Study). Int J Obes. 1998;22:66–72
  18. Chu NF, Rimm EB, Wang DJ, et al.  Clustering of cardiovascular disease risk factors among obese schoolchildren (the Taipei Children Heart Study). Am J Clin Nutr. 1998;67:1141–1146
  19. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973;19:1350–1356
  20. Stavropoulos WS, Crouch RD. A new calorimetric procedure for the determination of serum triglyceride. Clin Chem. 1974;20:857
  21. Wamick GR, Benderson J, Albers JJ. Dextran sulfate-Mg precipitation procedure for quantification of high density lipoprotein-cholesterol. Clin Chem. 1982;28:1379–1388
  22. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of low density lipoprotein-cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  23. Marcovina SM, Albers JJ, Dati F, et al.  International federation of clinical chemistry standardization projects for measurements of apolipoprotein A-1 and B. Clin Chem. 1972;18:499–502
  24. Robert WL, Sedrick R, Moulton L, et al.  Evaluation of four automated high sensitivity C-reactive protein method (implications for clinical and epidemiological applications). Clin Chem. 2000;46:461–468
  25. Castell JV, Andus T, Kunz D, et al.  Interleukin-6 (the major regulator of acute-phase protein synthesis in man and rat). Ann N Y Acad Sci. 1989;557:87–101
  26. Neumann FJ, Ott I, Gawaz M, et al.  Cardiac release of cytokines and inflammatory responses in acute myocardial infraction. Circulation. 1995;92:748–755
  27. Gauldie J, Richards C, Northemann W, et al.  IFNb2/BSF/IL-6 is the monocyte-derived HSF that regulates receptor specific acute phase gene regulation in hepatocytes. Ann N Y Acad Sci. 1989;557:46–59
  28. Agrawal A, Kilpatrick JM, Volanakis JE. Structure and function of human C-reactive protein. In:  Mackiewicz A,  Kushner I,  Baumann H editor. Acute phase proteins. molecular biology, biochemistry, and clinical applications. Boca Raton: CRC Press;; 1993;p. 79–92
  29. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med. 1990;7:147–159
  30. Banks RE, Forbes MA, Storr M, et al.  The acute phase response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 1995;102:217–223
  31. Papanicolaou DA, Wilder RL, Manolagas SC, et al.  The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127–137
  32. Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol. 2000;27:2351–2359
  33. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke (finding from the Third National Health and Nutrition Examination Survey). Arterioscler Thromb Vasc Biol. 2000;20:1052–1056
  34. Mohamed-Ali V, Goodrick S, Rawesh A, et al.  Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-[alpha], in vivo. J Clin Endocrinol Metab. 1997;82:4196–4200
  35. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6. J Clin Endocrinol Metab. 1998;83:847–850
  36. Vgontzas AN, Papanicolaou DA, Bixler EO, et al.  Elevation of plasma cytokines in disorders of excessive daytime sleepiness (role of sleep disturbance and obesity). J Clin Endocrinol Metab. 1997;82:1313–1316
  37. Warren RS, Starnes HF, Gabrilove JL, et al.  The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg. 1987;122:1396–1400
  38. Hirokawa J, Sakaue S, Furuya Y, et al.  Tumor necrosis factor-alpha regulates the gene expression of macrophage migration inhibitory factor through tyrosine kinase-dependent pathway in 3t3–L1 adipocytes. J Biochem (Tokyo). 1998;123:733–739
  39. Hotamisligil GS, Arner P, Caro JF, et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–2415
  40. Kern PA, Saghizadeh M, Ong JM, et al.  The expression of tumor necrosis factor in human adipose tissue (regulation by obesity, weight loss, and relationship to lipoprotein lipase). J Clin Invest. 1995;95:2111–2119

PII: S0895-4356(02)00519-X

Journal of Clinical Epidemiology
Volume 56, Issue 1 , Pages 94-100 , January 2003

Article Tools

* Image Usage & Resolution